XML 56 R48.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue and Accounts Receivable Credit Concentration - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Disaggregation Of Revenue [Line Items]          
Primary sources of revenue, description     We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharmaceutical Services and other).    
Revenue recognized     $ 500    
Deferred revenue $ 676   $ 676   $ 324
Revenue | Minimum | Customer Concentration Risk | Medicare          
Disaggregation Of Revenue [Line Items]          
Concentration risk, percentage 40.00% 41.00% 40.00% 45.00%  
Up Front Cash Payments          
Disaggregation Of Revenue [Line Items]          
Deferred revenue $ 900   $ 900    
Other Long-term Liabilities          
Disaggregation Of Revenue [Line Items]          
Non-current deferred revenue $ 300   $ 300   $ 300